Ketamine for Chronic Pelvic Pain in Baltimore
Targeting visceral central sensitization — when pelvic pain has outlasted its original cause.
Ketamine for pelvic pain in Baltimore is an off-label IV infusion — $1,499.99 per session, $1,125 for Vitality Circle members — evaluated for chronic pelvic pain syndrome (CPPS): interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis-related pain in women, vulvodynia, and chronic prostatitis/CPPS in men. Every infusion is anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD, a Johns Hopkins anesthesiologist, with a Certified Registered Nurse Anesthetist (CRNA) on-site. Despite distinct peripheral causes, these conditions share visceral central sensitization — NMDA receptor hyperactivity in the spinal cord that keeps amplifying pelvic pain after the original driver has been treated — and that centrally amplified pain layer is what ketamine targets. Your urologist, gynecologist, and pelvic-floor physical therapist continue their care; FDA-approved first-line treatments for endometriosis and IC/BPS come first. Ketamine is off-label and results vary. $1,499.99/session non-member · $1,125/session Vitality Circle member.
Mon–Fri: 1PM–8PM · Sat: 10AM–2PM
513 Bayview Blvd, Canton, Baltimore MD 21224
(443) 563-1059
Tell Us About Your Situation
Answer a few quick questions — our clinical team reaches out within 1 business day to discuss whether ketamine therapy may be right for you.
Your information is confidential. A clinical team member follows up within 1 business day.
What Chronic Pelvic Pain Actually Is — And Why It Has Been So Hard to Treat
If this sounds familiar, it is because chronic pelvic pain is one of the most consistently dismissed pain conditions in medicine. The reason so many tests come back inconclusive is not because nothing is wrong — it is because the most important pathological change is in the central nervous system, not in the pelvic organs themselves. Visceral central sensitization — NMDA receptor hyperactivity in the spinal cord amplifying pelvic pain signals — is the driver of chronic pelvic pain that no pelvic ultrasound, cystoscopy, or laparoscopy can reveal. It is measurable. It is defined. It is real. And it is the mechanism that ketamine's NMDA blockade directly targets.
Chronic pelvic pain syndrome (CPPS) is defined as persistent pelvic pain lasting 3 or more months — either continuously or intermittently — that is severe enough to cause functional disability or require medical care. It affects an estimated 15% of women and is the most common urological complaint in men under 50. Despite this prevalence, it remains chronically underfunded in research, underrecognized in medical training, and undertreated in clinical practice. The conditions it encompasses have different peripheral origins but share the same neurological mechanism: visceral central sensitization that sustains and amplifies pain independently of whatever initiated it.
CPPS Conditions Evaluated — And What to Try First
Chronic bladder pain, urgency, and frequency in the absence of infection or other identifiable cause. Involves mast cell activation, urothelial dysfunction, and neurogenic bladder inflammation — plus, in chronic presentations, visceral central sensitization that amplifies bladder afferent signals in the spinal cord. Treatment-refractory IC/BPS is among the most painful CPPS conditions.
Pentosan polysulfate (Elmiron) — FDA-approved but associated with retinal toxicity requiring ophthalmological monitoring. Intravesical DMSO, heparin. Dietary modification. TCAs (amitriptyline). Ketamine evaluated for central sensitization component in inadequate responders.
Endometriosis produces inflammatory pelvic pain through ectopic endometrial tissue, prostaglandin release, and nerve fiber invasion of lesions. In chronic cases, central sensitization develops — sustaining pain beyond lesion activity and explaining why hormonal suppression or surgical excision often provides incomplete relief.
GnRH agonists: elagolix (Orilissa), leuprolide (Lupron). Combined oral contraceptives. Progestins. Surgical excision of lesions — often the most effective structural approach. Ketamine evaluated for central sensitization when pain persists despite hormonal or surgical treatment.
Chronic vulvar pain, burning, or discomfort without an identifiable cause — including vestibulodynia (localized, provoked) and generalized vulvodynia. Involves peripheral sensitization of vulvar nerve endings and, in chronic cases, visceral central sensitization amplifying genital afferent signals. Profoundly affects quality of life, relationships, and psychological wellbeing.
Topical lidocaine, TCAs, gabapentin, and pelvic floor PT have evidence — none are FDA-approved for vulvodynia. Ketamine's visceral central sensitization mechanism is evaluated for inadequate responders without a clear first-line pharmacological standard to exhaust.
The most common urological diagnosis in men under 50. Persistent pelvic, perineal, or genital pain — often with urinary and ejaculatory symptoms — without evidence of bacterial infection. Involves visceral central sensitization in thoracolumbar spinal segments receiving pelvic afferent input. Profoundly underdiagnosed and undertreated.
Alpha-blockers (tamsulosin), antibiotics, and pelvic floor PT are standard approaches — none are FDA-approved for CP/CPPS. Ketamine's visceral central sensitization mechanism is evaluated for refractory presentations without a pharmacological standard to exhaust first.
For endometriosis and IC/BPS specifically, the following should be explored with your OB/GYN or urologist before ketamine evaluation. Vulvodynia and CP/CPPS have no FDA-approved specific alternatives — making ketamine evaluation more immediately relevant.
Elagolix (Orilissa) and leuprolide (Lupron) suppress estrogen to reduce endometriotic lesion activity and associated pain. Significant hormonal side effects (bone density, menopausal symptoms). Combined oral contraceptives and progestins are often tried first as better-tolerated hormonal suppression. Surgical excision addresses structural lesions and is often the most effective approach when lesions are extensive.
The only FDA-approved oral treatment for IC/BPS. Provides a layer of protection to the urothelial surface — addressing the bladder lining dysfunction component of IC/BPS. Important note: associated with pigmentary maculopathy (retinal toxicity) with long-term use — ophthalmological monitoring is recommended. Intravesical treatments (DMSO, heparin) offer alternatives for inadequate oral responders.
Vulvodynia and male CP/CPPS have no FDA-approved condition-specific pharmacological treatments. This makes ketamine evaluation more immediately clinically relevant for these presentations — there is no established pharmacological first-line to exhaust before ketamine consideration. Pelvic floor physical therapy and conservative measures should be tried first, but the pharmacological landscape is limited compared to endometriosis or IC/BPS.
Visceral Hyperalgesia — Why Pelvic Pain Is Mechanistically Distinct
Pelvic pain is not simply somatic pain in a different location. Visceral afferent pain pathways have distinct properties from somatic afferents that explain many of the features patients describe: the diffuse, poorly localized quality of pelvic pain; the referred pain to the lower back, thighs, and rectum; and the way that treating one pelvic organ often improves symptoms in adjacent structures.
Visceral afferent fibers from pelvic organs project to broad spinal cord segments — not to the precise dermatomal territories of somatic nerves. They converge extensively with somatic afferents in the dorsal horn, producing visceral-somatic convergence — where sensitization of visceral afferents amplifies responses to somatic inputs in the same spinal segment. This is why bladder pain is felt in the lower abdomen and thighs, not just the bladder. Why endometriosis pain radiates to the lower back. Why pelvic floor muscles become chronically tensed in response to visceral pain.
Visceral central sensitization occurs when NMDA receptors in the thoracolumbar spinal cord segments receiving pelvic afferent input become hyperactive — amplifying visceral pain signals beyond what peripheral organ pathology predicts. Once established, visceral central sensitization is self-sustaining — generating pelvic pain independently of ongoing peripheral bladder inflammation, endometriotic lesion activity, or prostate pathology. This is why endometriosis patients continue to have pain after successful surgical excision. Why IC/BPS pain persists after treatment of bladder pathology.
References: Giamberardino MA et al. (2010). Viscero-visceral hyperalgesia: characterization in different clinical models. Pain 151(2):307-22 (PMID 20638177). · Wesselmann U (2001). Neurogenic inflammation and chronic pelvic pain. World J Urol 19(3):180-5 (PMID 11469605). · Woolf CJ (2011). Central sensitization: implications for the diagnosis and treatment of pain. Pain 152(3 Suppl):S2-15 (PMID 20961685).
The Trauma-Pelvic Pain Axis — What the Research Shows
The connection between trauma, PTSD, and chronic pelvic pain is among the strongest and most clinically important associations in the CPPS literature. This is not a suggestion that pelvic pain is psychological. It is a description of specific, measurable neurobiological pathways through which adverse experiences directly amplify visceral pelvic pain.
Research consistently demonstrates that adverse childhood experiences, sexual trauma, and chronic stress significantly increase the risk of developing chronic pelvic pain — and that co-occurring PTSD worsens pelvic pain severity, treatment response, and quality of life. The mechanism is neurobiological, not psychological:
- HPA axis dysregulation: PTSD produces chronic cortisol dysregulation that sensitizes visceral afferent pathways — lowering the threshold for pelvic pain signals to trigger spinal cord responses.
- Descending pain facilitation: PTSD activates descending pain facilitatory pathways from the amygdala and periaqueductal gray — directly amplifying visceral pelvic pain through the same spinal cord segments receiving pelvic organ input.
- Shared NMDA pathways: the fear memory consolidation of PTSD and the visceral central sensitization of CPPS both involve NMDA receptor hyperactivity — ketamine's mechanism addresses both simultaneously through the same glutamatergic system.
- Sympathetic nervous system activation: chronic sympathetic activation from PTSD increases pelvic floor muscle tension, bladder sensitivity, and inflammatory signaling in pelvic tissue.
References: Latthe P et al. (2006). Factors predisposing women to chronic pelvic pain: systematic review. BMJ 332(7544):749-55 (PMID 16484239). · Meltzer-Brody S et al. (2007). Trauma and posttraumatic stress disorder in women with chronic pelvic pain. Obstet Gynecol 109(4):902-8 (PMID 17400852).
How Ketamine Works for CPPS — And the Evidence Behind It
Visceral Afferent NMDA Blockade
Ketamine's NMDA receptor blockade in the spinal cord dorsal horn directly interrupts the visceral afferent signals from pelvic organs that have become pathologically amplified through central sensitization. By blocking the NMDA receptors through which visceral central sensitization is maintained, ketamine may reduce the spinal cord amplification sustaining pelvic pain independently of the peripheral organ pathology — lowering overall visceral hypersensitivity across pelvic structures.
Cross-Organ Sensitization Interruption
Because all pelvic organs share spinal cord segments, resetting the visceral central sensitization through NMDA blockade may reduce pain sensitivity across the entire pelvic sensitization network simultaneously — not just in one organ. A patient with overlapping IC/BPS, pelvic floor tension, and bowel symptoms driven by shared visceral central sensitization may notice improvement across multiple symptoms from treatment that targets the shared spinal cord mechanism rather than each organ individually.
Descending Inhibition Restoration
Chronic pelvic pain — particularly in the context of a co-occurring mental health condition — is associated with impaired descending pain inhibition from supraspinal centers that normally suppress spinal cord pain transmission. Ketamine's synaptogenic effects in prefrontal circuits may restore some of this descending inhibitory capacity — reducing pelvic pain not only through spinal NMDA blockade but through restored brain-to-spinal-cord pain modulation.
Established neurogenic inflammation and central sensitization as key mechanisms of chronic pelvic pain — documenting that visceral afferent sensitization drives persistent pelvic pain independently of peripheral organ pathology. Provided the mechanistic foundation for understanding why organ-specific treatments often provide incomplete relief and why central sensitization-targeted therapy is clinically justified in CPPS.
Prospective clinical study of patients with two co-existing visceral pain conditions — including endometriosis or dysmenorrhea alongside urinary stones, and IBS alongside dysmenorrhea — showing that co-existing pelvic and visceral conditions mutually amplify each other and produce referred muscle hyperalgesia, and that treating one condition also reduced pain from the other. The authors attribute this cross-organ effect to sensitization of viscero-viscero-somatic convergent neurons in the spinal cord — the direct clinical basis for cross-organ sensitization in CPPS.
Systematic review of factors predisposing women to chronic pelvic pain — finding strong associations with physical and sexual abuse, PTSD, and adverse childhood experiences. Documented that trauma history is one of the strongest predictors of CPPS severity and treatment response. Provided the epidemiological basis for the trauma-pelvic pain axis and the clinical relevance of ketamine's dual mechanism.
The foundational paper establishing NMDA receptors as the central mechanism of central sensitization — directly applicable to the visceral sensitization that sustains chronic pelvic pain. Established that NMDA receptor hyperactivity in the spinal cord amplifies pain signals from both somatic and visceral afferents — making NMDA-targeted therapy (ketamine) mechanistically relevant to visceral pelvic pain regardless of peripheral origin.
Pelvic Pain Ketamine Pricing at Vita Nova
| Service | Non-Member | Vitality Circle Member | Saving |
|---|---|---|---|
| Ketamine — Chronic Pain / session Off-Label | $1,499.99 | $1,125 | $374.99/session |
If you have a documented co-occurring mental health condition alongside chronic pelvic pain: treating it may reduce pelvic pain through restored descending pain inhibition — which is why a single evaluation considers your whole pain picture. See our co-occurring depression & chronic pain page.
Self-pay, with a superbill. Every session is anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD — Johns Hopkins faculty and Chief of Thoracic Anesthesia at Johns Hopkins Hospital — in a private treatment room with continuous cardiac and vital-sign monitoring, so the price reflects physician-level, monitored care rather than a walk-in drip. Vita Nova is self-pay for ketamine and provides an itemized superbill you can file with your insurance (see our ketamine insurance guide). HSA and FSA accepted; Community Heroes discounts available. Vitality Circle membership ($99.99/month) pays for itself on a single session — the member rate saves $374.99, more than the membership — and adds one included monthly perk (1 standard IV drip, 2 IM shots, 2 IV pushes, or 1 shot + 1 push) plus 25% off premium IVs. Sessions determined individually — first visit? Read the new patient guide. Pricing August 2026 — subject to change. Full pricing guide →
Complementary Treatments Supporting Pelvic Pain Relief
Magnesium modulates NMDA receptor sensitivity directly relevant to ketamine's visceral central sensitization mechanism. Magnesium deficiency worsens NMDA excitability and amplifies visceral pain signals. Magnesium also plays a role in smooth muscle relaxation relevant to pelvic floor hypertonicity and bladder wall spasm common in CPPS. Common in women with endometriosis and premenstrual-pattern CPPS.
B vitamins support mood neurotransmitter synthesis and nerve function depleted by co-occurring low mood and long-term medication use common in CPPS. B12 supports myelin integrity relevant to the neuropathic component of vulvodynia and CP/CPPS. Folate and B6 support serotonin synthesis relevant to descending pain inhibition — the pathway that chronic stress impairs in pelvic pain patients.
Heavy or prolonged menstrual bleeding (menorrhagia) — common in endometriosis and other gynecologic pelvic pain conditions — is a leading cause of iron-deficiency anemia, which adds fatigue, brain fog, and reduced stamina on top of chronic pain. Iron does not cause the pelvic pain itself, but when bloodwork confirms iron-deficiency anemia, IV iron restores stores faster than oral iron many patients absorb poorly or cannot tolerate — lifting the fatigue layer that makes the pain harder to manage.
Chronic visceral pain and a co-occurring mental health condition together produce significant cellular energy depletion — central nervous system metabolic demands are elevated by constant pain processing and mood dysregulation. NAD+ IV Therapy supports mitochondrial energy at the cellular level — providing the neural energy substrate that supports both the neuroplastic changes ketamine aims to initiate and the recovery from chronic pain's metabolic demands.
Inflammatory signaling is prominent in both endometriosis (prostaglandin-driven) and IC/BPS (mast cell-driven neurogenic inflammation). High-dose IV Vitamin C addresses oxidative stress and cytokine load relevant to these inflammatory pelvic pain components — complementing ketamine's central sensitization mechanism with anti-inflammatory peripheral support for the endometriosis and IC/BPS populations specifically.
Clinical note: These wellness services are not treatments for CPPS and are not part of Vita Nova's ketamine protocols. Always discuss supplemental therapy with your OB/GYN, urologist, or prescribing physician — particularly regarding interactions with hormonal therapies, Elmiron, or other pelvic pain medications.
Special Pricing for Those Who Serve
Nurses, healthcare workers, teachers, and veterans all carry elevated rates of chronic pelvic pain — through occupational stress, physical demands, and the trauma exposures that disproportionately affect these populations.
Chronic Pelvic Pain & Ketamine — Questions Answered
Real, high-intent questions from CPPS patients evaluating ketamine and IV therapy in Baltimore.
Your Pain Is Real —
And There Is a Mechanism That Reaches It
If IC/BPS, endometriosis, vulvodynia, or CP/CPPS has not responded to established treatments — or if your pain has outlasted every procedure — ketamine's visceral central sensitization mechanism targets what organ-specific treatment cannot: the NMDA-mediated amplifier in the spinal cord. Off-label, self-pay with an itemized superbill you can file with your insurance. Community Heroes discounts available. Your privacy is respected throughout.
Medically reviewed by Dr. Brijen L. Joshi, MD — Founder & Medical Director, Johns Hopkins Assistant Professor of Anesthesiology & Critical Care Medicine.
Canonical URL: https://vitanovawellnessclinic.com/ketamine-pelvic-pain-baltimore/ · Last reviewed August 2026
